ArticleFolia microbiologica2025
Nisin: The powerhouse metabolite of lactobacillus strains to defeat prostate cancer by targeting PCA3 lncRNA, apoptosis, and cell cycle pathways.
Article in Folia microbiologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer remains a major global health challenge, driving the need for innovative therapies. Nisin, an antimicrobial peptide from Lactobacillus lactis, has shown anticancer effects in various malignancies, yet its impact on prostate cancer and the prostate cancer antigen 3 (PCA3) long non-coding RNA (lncRNA) remains unstudied. This research aimed to investigate nisin's anticancer properties in prostate cancer cells, focusing on PCA3 lncRNA, apoptosis, and cell cycle pathways. Human prostate adenocarcinoma (LNCaP) and normal human foreskin fibroblast (HFF2) cells were treated with nisin. Cell viability was measured using MTT assays, while apoptosis and cell cycle progression were assessed via flow cytometry. Quantitative PCR (qPCR) evaluated gene expression of PCA3 lncRNA, apoptosis-related genes, cell cycle regulators, and PCA3-associated microRNAs and mRNAs. In-silico analysis of TCGA-PRAD data explored PCA3's regulatory network. Nisin selectively reduced LNCaP cell viability (IC₅₀: 370.7 μM at 24 h, 177.2 μM at 48 h) compared to HFF2 cells (IC₅₀: 887.8 μM at 24 h, 406.5 μM at 48 h). It induced time-dependent apoptosis and G1 phase cell cycle arrest in LNCaP cells. Nisin downregulated PCA3 lncRNA expression, upregulated miR-132-3p and miR-1261, and altered SREBP1 and PRKD3 gene expression, modulating the PCA3 regulatory network. This study is the first to explore nisin's anticancer effects in prostate cancer, uniquely targeting PCA3 lncRNA and its downstream regulatory pathways. Nisin demonstrates potent anticancer effects in prostate cancer cells by inducing apoptosis, arresting cell cycle progression, and modulating the PCA3 lncRNA network, suggesting its potential as a novel therapeutic agent.
Indexed as
Identifiers
41105372What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.